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 The most challenging complication after total joint replacement is the 
periprosthetic joint infection (PJI). Staphylococcus aureus is a commensal 
bacterium and a human pathogen. It is responsible for more than half of the 
PJI. We demonstrated that synovial fluid has antimicrobial properties against 
S. aureus and the iron restriction is one of the mechanisms used for the host 
to prevent bacterial growth, and is even able to increase killing of S. aureus. 
We have shown a clear role of transferrin as a restrictive factor in synovial 
fluid that functions by iron starving the bacteria and sensitizing them to killing 
by some other unknown factor, such as antimicrobial peptides. The 
development of animal models would help to improve our understanding of 
the pathogenesis of PJI. We also successful established an animal model of 
PJI, which allows the temporal observation of disease progression and gives 
the ability to track different bacterial mutants. 
SUMMARY FOR LAY AUDIENCE 
The most challenging complication after total joint replacement is the 
periprosthetic joint infections (PJI). Staphylococcus aureus is the bacteria 
responsible for more than half of the infections. We demonstrated that 
synovial fluid has antimicrobial properties against S. aureus. The iron is the 
most important nutrient used for bacteria and we found that the iron 
restriction is one of the mechanisms used for the host to prevent bacterial 
growth, and is even able to increase killing of S. aureus. We have shown a 
clear role of one of the proteins in synovial fluid (transferrin) as a restrictive 
factor in synovial fluid that functions sensitizing the bacteria for killing by 
some other unknown factor, such as antimicrobial peptides. The 
development of animal models would help to improve our understanding of 
the PJI. We successful established an animal model of PJI, which allows the 
temporal observation of disease progression. 
 
KEYWORDS:  Staphylococcus, aureus, periprosthetic, infection, synovial 
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1.1 Introduction to immune response 
 
 Microbes are ubiquitous throughout the gastrointestinal tract and on the 
human skin, yet these bacteria rarely cause infection. Epithelial cells lining 
the skin, respiratory, gastrointestinal, urogenital tracts provide a physical 
barrier, which microbes are unable to cross. In addition to the physical 
barrier these environments also produce several chemical barriers, such as 
the low pH of the upper gastrointestinal tract. Moreover, human skin has a 
high amount of salt and fatty acids, which prevent the growth of many 
bacteria (1, 2). However, when these barriers are breached by some means, 
pathogens will be able to bypass the physical and chemical barriers allowing 
them to invade into the host tissues. 
 If pathogens are able to circumvent the initial barriers, they may then be 
faced with the humoral component of innate immunity including the 
complement system. The complement system consists of small soluble 
proteins. When activated the complement system allow a proteolytic 
cascade resulting in the formation of the membrane attack complex (MAC). 
The MAC forms transmembrane channels leading to osmotic lysis of the 
host cells (3).  
 Another mechanism of defense of many host tissues to infection is 
known as colonization resistance, whereby commensal bacteria colonizing 
the host compete with pathogens for nutrients and attachment sites. Iron is 
an essential micronutrient for virtually all microorganisms owing to its wide 
range of redox potentials. It serves as the catalytic center of enzymes 
involved in critical cellular processes such as DNA synthesis and electron 
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to its tendency to form insoluble oxyhydroxides under aerobic conditions at a 
neutral pH. The amount of iron available in the host environment is further 
reduced by sequestration into proteins such as transferrin and lactoferrin, 
virtually no free iron exists in living organisms (4, 5, 6).  
 
1.2 Staphylococcus aureus as a pathogen 
   
 Staphylococcus aureus is both a commensal bacterium and human 
pathogen. Many people are colonized with S. aureus and it is often present 
asymptomatically on parts of the human body such as skin, skin glands, and 
mucous membranes, including nares and guts of healthy individuals. It is 
responsible for many different infections in the human population as 
bacteremia, infective endocarditis, skin and soft tissue infections, 
pleuropulmonary, as well as osteoarticular and device-related infections (7, 
8).  
 S. aureus, a member of the family Micrococcaceae, is a Gram-positive 
coccus whose cells tend to occur either singly or if dividing cells do not 
separate, form pairs, tetrads and distinctive irregular “grape-like” structures 
(8, 9). 
 These organisms were first described and classified as Staphylococcus 
in 1882 by the Scottish surgeon Sir Alexander Ogston (8, 10). Two years 
later a German physician, Friedrich J. Rosenbach described 2 pigmented 
colonies of Staphylococcus and proposed the nomenclature S. albus (Latin 




 S. aureus is one of the first described pathogens and it still is one of the 
most common causes of infections in humans. It is important due to its 
ability to cause infections as well as its capacity to adapt to diverse 
environmental conditions. It can affect the bloodstream, skin and soft 
tissues, and lower respiratory tract and can cause infections related to 
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 One of the main issues associated with S. aureus is its ability to acquire 
resistance against multiple antibiotics, complicating treatment. Resistance in 
S. aureus emerged 2 years after the introduction of penicillin. The 
semisynthetic methicillin antibiotic was developed in the late 1950s, and the 
resistant strain (MRSA) was clinically identified in 1960 (8, 12). 
 The expansion of MRSA began in the late 1970s and this has turned 
into a nonstop evolutionary journey. MRSA resistant to gentamicin emerged 
in Europe and the United States (US), continued by Australia and Latin 
America until in 2003, this microorganism was isolated in nearly 60% in US 
intensive care units (12, 13). 
 In Canada, MRSA was first documented in 1964 and the first outbreak 
occurred in 1978 at the Royal Victoria Hospital in Montreal. From the time of 
its emergence until the 1980s, MRSA was essentially a hospital-acquired 
pathogen. Today, these isolates of MRSA are called health care–associated 
MRSA (HA-MRSA) and are highly resistant to most oral antibiotics (14). 
 Infections due to methicillin-resistant strains of S. aureus are associated 
with higher mortality rates than infections caused by methicillin-susceptible 
strains. In addition, they result in increased lengths of hospital stays as well 
as associated health care costs. The prevalence and the epidemiology of 
MRSA are constantly changing, with novel MRSA clones appearing in 
different geographical regions. Therefore, continuous vigilance for MRSA 
through monitoring the characteristics, host specificity, and modes of 
transmission is required (8). 
 S. aureus is one of the major causes of hospital and community-
acquired infections, resulting in serious consequences. Although many 
actions to reduce healthcare-associated infections such as better antibiotic 
selection, isolation of infected patients, skin and nose decontamination 
treatment prior to surgery, and improved hand hygiene helped to reduce 
MRSA infections, its prevalence is still increasing (12). 
 
1.2.2 Resistance mechanism 
 
 The success of S. aureus as a human pathogen is attributable to its 
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antibiotics used to treat it (12, 15). S. aureus has wall glycopolymers, 
including wall teichoic acid (WTA), peptidoglycan, lipoteichoic acid, and 
capsular polysaccharides. These bacterial surface glycopolymers are 
recognized by serum antibodies and a variety of pattern recognition 
molecules leading to complement activation and host defense responses 
(16). 
 Survival of bacteria depends of the biofilm formation (17). The biofilm is 
a polymeric matrix that adheres to prosthetic material. It acts as a sanctuary 
site where S. aureus is relatively protected from antimicrobial agents and the 
host immune response. In addition, organisms within a biofilm generally 
enter a stationary phase of growth and are thus much more resistant to 
antimicrobial killing (7). 
 Understanding the development of staphylococcal biofilms is essential 
to generate new treatment strategies for these infections. A known basic 
model consists of three stages: 1) attachment, 2) accumulation/maturation, 
and 3) detachment/dispersal. The use of new technologies (e.g. 
BioFlux1000 system) in recent studies allowed researchers to observe the 
development of the S. aureus biofilm in real time. This consists of 5 stages: 
attachment, multiplication, exodus, maturation, and dispersal (18). 
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 During growth and division, bacteria biosynthesize cell wall, which is a 
polymer made up of the peptidoglycan as the principle building unit. The 
peptidoglycan is composed of repeats of the disaccharide N-
acetylglucosamine (NAG)-N-acetylmuramic acid (NAM) with peptide stems 
on the NAM unit. The peptide stems of neighboring peptidoglycan strands 
are the points of crosslinking to give the mature cell wall. Synthesis of the 
peptidoglycan backbone is carried out by the catalytic function of 
transglycosylases, with transpeptidases - also referred to as penicillin 
binding proteins (PBPs) - performing the crosslinking reaction. Coordination 
of these reactions is an elaborate process, which ultimately results in the 
cell-wall structure (17). The final step of the biofilm life cycle involves the 
dispersal of cells with the ability to travel to distal sites to disseminate 
infection. The mechanism by which S. aureus regulates this step is largely 
mediated by the accessory gene regulator (agr) quorum-sensing system. 
The agr system responds to cell density through the accumulation of signal 
molecules, allowing for dispersal to occur once a threshold density is 
reached, leading to bacteremia (18). 
 The penicillin resistance was reported in 1942, and the mechanism was 
described in the mid-1940s based on an inducible beta-lactamase. 
Methicillin was introduced in 1959 and two years later its resistance was 
reported, beginning the “era” MRSA (12, 19).  
 The methicillin resistance is not due to beta-lactamase production but 
due to the expression of an additional penicillin-binding protein (PBP2a) with 
low affinity for beta-lactams (8, 9). PBP2a is encoded by chromosomal gene 
mecA, located in a mobile genomic element known as the staphylococcal 
cassette chromosome (SCC), in this case SCCmec. The mecA gene is 
widely distributed among S. aureus as well as coagulase-negative 
staphylococci. Therefore, it has been speculated that the methicillin 
resistance determinant (mec determinant) is freely transmissible among 
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1.3 Periprosthetic Joint Infections (PJIs) 
 
 Joint replacement is a highly effective intervention that significantly 
improves the quality of life of the patient, relieves symptoms, restores joint 
function, and improves mobility and independence in patients with severe 
osteoarthritis, inflammatory arthritis, post-traumatic arthritis and many 
conditions that affect the articular surfaces (21). 
 The number of arthroplasty procedures performed every year is 
increasing, with a projected annual volume of more than 4 million cases by 
2030 in the United States (22). As a result of the increasing volume of 
primary procedures, there is an anticipated increase in revision arthroplasty. 
The leading cause of revision surgery is a periprosthetic joint infection (PJI), 
which is one of the most challenging complications after total joint 
arthroplasty (23, 24). Recent studies estimate risk of infection to be 




Figure 2: The projected number of: a) Primary THA and TKA procedures in the United States 






 The evolution of total joint arthroplasty in recent times in terms of design 
and fixation of implants, has led to improvements in the control of 
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over the last two to three decades, mostly due to operating room 
environments and operative techniques (27). The use of prophylactic 
antibiotics and other precautions has helped reduce the prevalence of 
clinically recognized periprosthetic infection from nearly 10% in the early 
years in which arthroplasty was performed to less 1% in some series (26).  
 Despite this decline, periprosthetic infection is associated with immense 
physiological, psychological, and financial costs (26). Numerous challenges 
can be associated with the development of a PJI that may include the need 
for multiple operations, a long period of disability for the patient, and 
sometimes, a suboptimal result. The economic and psychological burden of 
this complication leads to an ongoing effort to develop strategies to help 
prevent and reduce its incidence to a minimum (28). 
 Pulido et al (28), in their study confirmed that some previously 
implicated risk factors, such as wound drainage, hematoma formation, a 
history of rheumatoid arthritis, prolonged operative time and urinary tract 
infection, are still important predisposing factors for development of a PJI. 
Other risk factors that were obtained from this analysis were prolonged 
hospital stays, blood transfusions and obesity. 
 
Table 1: Host risk factors classification. 
 
Host risk factors of PJIs 
Modifiable host risk 
factors 
Active infection, alcoholism, cardiovascular disease, kidney 
disease, diabetes mellitus, immunosuppression, intra-articular 




Age, gender, bariatric surgery, chronic anticoagulation, 
previous joint surgery, previous joint infection, transplant.  
 
 
 Intra-articular steroid injections are widely used for the symptomatic 
relief of osteoarthritis of the knee before elective total knee arthroplasty. 
Cancienne et al (29) concluded that patients who received an intra-articular 
injection between 0 and 3 months before surgery had an increased risk of 
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received intra-articular injections more than 3 months ago. Schairer et al 
(30), obtained similar results about intra-articular corticosteroid injections in 
the hips. 
 Diabetes mellitus has been considered a well-established risk factor for 
surgical site infections (SSIs) following many surgical procedures. However, 
it remains a controversial issue regarding of the development of PJIs after 
primary total hip and knee replacement. In a high quality study utilizing the 
Mayo Clinic Total Joint Registry (31), diabetes was reported not to be a risk 
factor for PJIs when the variables were adjusted for age, gender, BMI, type 
of surgery, ASA score and operative time. Martinez-Huedo et al (32) 
obtained similar conclusions, demonstrating that the diabetes mellitus was 
not associated with increased PJIs in patients undergoing THAs. Despite 
this, The American Diabetes Association (33) supports the control of glucose 
in all patients with diabetes mellitus and in those who receive therapies 
associated with hyperglycemia, based on the evidence that the prevalence 
of hyperglycemia in hospitalized patients is high and the Hospitalization 
period offers the opportunity to diagnose unrecognized diabetes mellitus. 
 The screening of MRSA colonization in all patients before an elective 
total joint arthroplasty (TJA) is a relevant topic in relationship to prevention of 
PJIs. Several studies determined that high-level nasal carriage of S. aureus 
was a significant independent factor with a relative risk of developing a SSI 
and the quick, inexpensive, and simple nasal decolonization of the carriers 
on admission is an effective technique to reduce the PJIs (34, 35). 
 
1.3.2 Diagnosis and Classification 
  
 In order to diagnose a disease with certainty and determine its 
prevalence, it is important to define the criteria for its diagnosis (26). The 
different guidelines recommend that clinicians should suspect a PJI in 
patients who have undergone a total joint arthroplasty (TJA) when they 
present with any of the following signs and symptoms: 
 Persistent wound drainage over a joint prosthesis. 
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 Chronic painful prosthesis at any time after prosthesis 
implantation, particularly in the absence of pain-free interval in 
the first years following implantation (36). 
 
Table 2: Musculoskeletal Infection Society (MSIS) criteria for a definite diagnosis of PJI (36). 
 
 
 The evaluation of patients with a painful TJA begins with a through 
history, physical examination, and joint specific radiographic imaging. 
Multiple surgeries on the same joint, history of prior PJI, history of surgical 
site infections of the same joint, comorbidities resulting in a 
immunocompromised state (i.e. diabetes mellitus, inflammatory arthropathy, 
etc.) or patients with increased risks of skin barrier penetrations (i.e. 
intravenous drug abuse, skin ulceration, chronic venous stasis, etc.) should 
be considered at higher risk for PJIs. Physical exam findings suggestive of 
PJIs include joint erythema, warmth, or large atraumatic effusion (37). 
 After the physical examination, the evaluation of the radiographic 
studies is very important. There are a few non-specific changes suggestive 
of chronic infection that may be apparent on plain radiographs. These 
include periosteal reaction, osteolysis, or generalized bone resorption in 
1. A sinus tract communicating with the prosthesis; or 
2. A pathogen isolated by culture from two separate tissue or fluid samples obtained from the 
affected prosthetic joint; or  
3. Four of the following six criteria exist: 
 a. Elevated serum erythrocyte sedimentation rate (ESR) or serum C-reactive protein 
(CRP) concentration. 
 b. Elevated synovial white blood cell (WBC) count. 
 c. Elevated synovial neutrophil percentage (PMN%). 
 d. Presence of purulence in the affected joint. 
 e. Isolation of a microorganism in one culture of periprosthetic tissue or fluid. 
 f. Greater than five neutrophils per high-power field in five high-power fields 
observed from histologic analysis of periprosthetic tissue at 400 times magnification. 
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absence of implant wear. The main role is to rule out other conditions such 
as implants wear or fractures (26). 
 No single laboratory test has perfect sensitivity and specificity for 
diagnosis infection. Screening test results that may suggest the possibility of 
infection include elevation of the erythrocyte sedimentation rate (ESR) and 
serum C-reactive protein (CRP) level more than three months after an 
arthroplasty (26, 37, 38). 
 One of the most important tests in the evaluation for potential 
periprosthetic infection is culture of the fluid aspirated from the joint (26). 
Synovial fluid analysis should include a total cell count and differential 
leukocyte count, as well as culture for aerobic and anaerobic organisms 
(21). The American Academy of Orthopaedic Surgeons (AAOS) clinical 
practice guidelines (39) suggest patients be off antibiotics for a minimum of 
2 weeks prior to obtaining intra-articular culture.   
 PJIs are typically classified according to the timing of symptom 
development and the mechanism of infection as acute, chronic and 
hematogenous infection (37).  
 
 Table 3: PJIs classification (Time). 
 
PJIs Classification (Time) 
Acute Within the first 4 weeks 
Chronic More than 4 weeks 
Acute hematogenous Secondary to another infection 
 
  
 Acute postoperative infections are a result of organisms that gained 
access to the joint during the operation, or soon after it, from the overlying 
skin or a draining wound. Infections of this type generally become 
symptomatic within a few days or weeks after the arthroplasty. Late chronic 
infections may result from organisms introduced during the operation, either 
from the air, from surgical instruments, or from the implant itself. The lag 
period is the time needed for the organisms to proliferate and induce 
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seeding of an arthroplasty site by organisms carried by the bloodstream 




 Prosthetic joint infection remains a serious problem, despite modern 
operative technologies, new implants and rigorous perioperative antibiotic 
prophylaxis. The therapeutic goal must remain prevention, but the treatment 
of established PJI aims for complete eradication of the infection with 
maintenance of the joint function (40). 
 Once the diagnosis of periprosthetic joint infection is confirmed, the 
characteristics of the infection are important. These include the duration of 
symptoms, patient immune status and overall health characteristics, history 
of periprosthetic joint infection in the current joint and all other joints, status 
of any joint wound, joint function expectations, and characteristics of the 
infecting organism. These data will dictate the surgical treatment selection 
(26). 
 An essential component of the care of patients with PJI is strong 
collaboration between all involved medical and surgical specialists (21). 
Treatment algorithms are typically dependent on the classification (37). 
 
1.3.3.1 Debridement, antibiotics, implant retention (DAIR) 
  
 Open debridement, antibiotics, irrigation and implant retention is an 
option less invasive and that decreases morbidity and could be the solution 
in patients with an early infection, within four to twelve weeks of surgery. 
Recent studies demonstrated a rate overall proportion of success 70% 
associated with DAIR in the treatment of infected THAs (41).  
 DAIR should be considered an urgent procedure, as the time period 
from the onset of symptoms until the operation has been reported to be an 
important factor affecting the success of the procedure. Type of infecting 
organism, duration of symptoms before intervention, type and duration of 
antibiotic therapy, age, presence of underlying inflammatory conditions, 
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comorbidities are known factors that affect the outcomes of DAIR (42, 43). 
Kunutsor et al (44), in their results showed that a longer duration between 
onset of symptoms to DAIR (≥ 21 days) is associated with lower infection 
control compared with a shorter duration (< 21 days).  
 Patient medical comorbidities are one consideration prior to DAIR; 
however, the effect of individual medical comorbidities on failure of DAIR is 
not clear (35). Obesity has been associated with the risk of PJI, however, no 
direct correlation has been found between the failure of DAIR treatment and 
high BMI when this is taken as a continuous variable (45). 
 Compromised host immunity may lead to inferior outcomes. Diseases 
such as diabetes mellitus and inflammatory arthritis increase the risk of 
primary PJI; however, their association with failure of DAIR is less clear. 
Although an optimized host maximizes the chances of success for DAIR; 
individual comorbidities by themselves do not appear to provide a 
contraindication to the procedure (44, 45). 
 Fink et al. (46), had successful outcome in 71.6% of patients overall, 
with 82.1% for early postoperative infections and 57.1% for acute 
hematogenous infections.  
 Regarding of analyses by specific infecting organism, the evidence 
suggests similar infection control for Gram negative and Gram positive 
bacteria. Further analysis confirmed higher infection control for streptococcal 
infection (89,5%) compared with staphylococcal species (75%) (44). 
Triantafyllopoulos et al. (47), concluded that infection by Staphylococcus 
aureus, particularly methicillin-resistant Staphylococcus aureus (MRSA), 
shown to be associated with high failure rates after DAIR. According that, 
DAIR should be discouraged when the chance of failure without removing 
the implant is very high. Therefore, chronic PJIs should be considered an 
absolute contraindication of this procedure, as a fully developed mature 
biofilm with the presence of "persister cells" excludes the possibility for cure 
without removal implant (48). 
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1.3.3.2 One stage exchange 
   
 One stage exchange arthroplasty was originally described by Buchholz 
et al. (49) and is used in several centers today, particularly in Europe. One-
stage exchange arthroplasty is similar to the two-stage procedure but the 
interval between removal of the arthroplasty and reimplantation of a new one 
is only a few minutes. The benefits are only one anesthetic procedure, 
shorter hospitalization, less cost and earlier recovery (50, 51). 
 In addition, strict preoperative, intraoperative and postoperative criteria 
must be considered to indicate this management. The correct patient 
selection, identification of bacteria preoperatively, aggressive soft tissue 
debridement, meticulous removal of the prior cement material and implants, 
specific postoperative antibiotic regimens are important for success of this 
procedure. It is essential to have an experienced surgical team and an 
infectious disease specialist (microbiologist) (51). 
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 There are several contraindications of a 1-stage exchange, including, 
but not limited to (40, 52): 
 Unidentified bacteria preoperatively; 
 Failure of >2 previous 1-staged procedures; 
 Infection involving the vascular/neurovascular bundle; 
 Lack of appropriate antibiotics;  
 Infection with a highly virulent organism. 
 
 Generally, the surgical technique consists of open aggressive 
debridement with removal of all components and cement, during which 
multiple samples are sent to microbiology before administration of antibiotics 
and the joint is irrigated with hydrogen peroxide and an antiseptic solution, 
and pulsatile lavage. The wound is then soaked in aqueous antiseptic 
solution and the wound edges are approximated. The patient is then 
redraped, the surgical team rescrubs, and new instruments are used. After a 
further lavage, implantation of a new prosthesis is performed using 
antibiotic-loaded cement (ALC) according to known sensitivities at a volume 
of 5% of the total weight of cement powder. Postoperatively, patients 
continue antibiotic therapy tailored to the sensitivities of intraoperative 
cultures for at least 6 weeks until inflammatory markers (CRP, ESR) and 
nutritional markers such as plasma albumin concentration return to stable 
limits. The change from intravenous to oral therapy is affected as soon as a 
full organism sensitivity profile is obtained and after consultation with 
infectious diseases team (52, 53). 
 Infection control using a single-stage strategy in selected patients is 
achieved in 67% to 95% of patients (53). The patients must be conscientious 
of the possible risks associated with one-stage exchange, for example: risk 
of recurrent infection rate 10-15%; reoperation for hematoma, wound 
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1.3.3.3 Two stage exchange 
 
 Two-stage reimplantation was first described by Insall et al. (54). 
Currently, it is the gold standard for the treatment of a chronic PJI. This 
involves a minimum of 2 surgeries for the patient, the first to remove the 
infected prosthesis, extensive debridement of nonviable tissues, irrigation 
and implantation of a temporary antibiotic-impregnated cement spacer; and 
once the infection is eradicated, and a second surgery to place a new 
prosthesis. Antibiotics are administrated based on the sensitivities of the 
infecting organisms (55, 56). 
 There are two relevant topics about the two-stage exchange, first is 
antibiotics-impregnated static cement spacer vs. articulating cement spacer; 
and second is the duration of therapy systematic antibiotics and the timing of 
reimplantation. 
 There is no clear consensus on the ideal type of spacer for 
management of PJIs of the hip and knee. The goal of the spacer is to 
preserve the joint space and reduce the soft tissue contracture while 
delivering high doses of antibiotics. Static spacers are generally 
recommended for cases with massive bone loss, lack of functional collateral 
ligaments, extensor mechanism disruption and the need for soft tissue 
reconstruction, while general functional improvement is expected with 
articulating spacers. The results for infection eradication are similar in 
individual studies (55). Park et al. (57) concluded that the articulating 
spacers have been shown to be associated with improved range of motion, 
better function, and also with the ability to facilitate ease of dissection at the 
second stage. However, few data are available on the incidence and type of 
spacer-related problems. Struelens et al. (58) found that there was a 57% 
incidence of spacer-specific problems, the most frequent being spacer tilting 
and medial lateral translation. Lanting et al. (59) found a spacer complication 
rate of 8.4%, but they did not include lateral and posterior subluxation cases 
due to these complications were common, probably secondary to 
inadequate soft tissue tensioning and incorrect position of the spacers. In 
addition, articulating spacers typically come in a limited number of sizes and 
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 Regarding the duration of therapy of systematic antibiotics and the 
timing of reimplantation, Insall et al. (54) suggest a protocol prolonged of 
intravenous antibiotics between the two stages of surgery (6 weeks). 
Several recent studies have questioned the standard, prolonged antibiotic 
therapy used in two-stage revision procedures for PJI. Infection and surgical 
trauma can cause the blood supply to the periarticular tissue to be 
attenuated, which prevents antibiotics administered systemically from 
reaching the desired site of action (60). Antibiotic-loaded cement spacers 
can maintain levels of antibiotics that are effective against infection for up to 
4 months following resection arthroplasty (61). Furthermore, a shorter 
course of intravenous antibiotic therapy decreases the likelihood of systemic 
toxicity and may reduce the emergence of drug-resistant organisms (62). 
The short period of antibiotic treatment has a successful eradication rate 
similar to that reported with longer regimens and is associated with less 
morbidity (61, 62). 
 
1.3.4 MRSA Periprosthetic Joint Infections 
  
 The management of infection after total joint replacement has been 
compounded by the emergence of organisms with resistance to some 
antibiotics (63).  
 In recent years, there has been a worrisome increase in number of PJIs 
caused by MRSA. According to recent studies, more than one half of PJIs 
treated in some institutions are caused by methicillin-resistant organisms.  
Approximately 47% of S. aureus clinical isolates in the United States are 
methicillin-resistant (64). 
 Patients with PJIs is associated with a higher number of readmissions, 
lengthier of hospitalization, an increased number of clinic visits and poor 
clinical outcomes (65). The impact of these factors imply that the costs of 
treating PJI caused by these organisms are higher compared to infections 
caused by methicillin-sensitive organisms (64). 
 Treatment of prosthetic joint infection creates an economic burden for 
the patient and healthcare facility with estimated costs higher than a 
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management of MRSA PJI has a higher cost due mainly to the length 
hospital stay. Similarly, the cost of treating intensive care unit admissions 
was also found to be higher compared to infections caused by methicillin-
sensitive organisms. 
 MRSA has become a prominent cause of infection in hip replacement, 
typically presenting early, reflecting its high virulence. Treatment is often 
prolonged, with a high rate of infection of the implant (63). Retention of the 
total hip or knee components, regardless of whether the components were 
well-fixed, generally was not successful when the infecting organisms were 
S. aureus or S. epidermidis that were resistant to currently available 
intravenous antibiotic therapies. The most successful treatment protocols 
include excision of all components, repeated surgical debridement, removal 
of all components and cement, and waiting for longer periods before 
reimplantation (a minimum of 5 weeks for knee arthroplasties, and 8 to 12 
weeks for hip replacements). In addition, the use of intravenous vancomycin 
and oral rifampin is indicated (62). 
 Given the increasing number of THA and TKA required for an aging 
population, infection with MRSA has implications for the future success of 
joint replacement surgery, the quality of life and of mortality (63). 
 
1.4 Synovial Fluid: Role in Periprosthetic Joint Infections  
 
 Osteoarthritis (OA) is a common disease that affects joints by causing a 
breakdown of cartilage and synovial fluid that results in increased wear, 
pain, inflammation and reduce mobility (67, 68).  
 The synovial fluid is the body´s natural synovial joint lubricant and it has 
been established which are its changes in OA (67, 68). Protein 
concentration, protein constituent fractions, osmolality, thermal stability, HA 
concentration plays an important role in OA (68). However, its role in the 
development of periprosthetic joint infections it is not well known. 
 Innate immunity against bacterial pathogens is present in many body 
fluids, including saliva, pleural, and peritoneal fluids (69). Although dental 
procedures are not risk factors for subsequent total hip or knee infection 
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the time following routine dental or gastrointestinal manipulations (70, 71). 
The relatively infrequent occurrence of septic arthritis in this setting suggests 
that although synovial joints frequently may be exposed to transient 
bacteremia events, synovial fluid likely possesses antimicrobial properties 
sufficient to the joints are able suppress these episodes and prevent 
progression to a clinically detectable septic arthritis.  
 The evidence suggests that in addition to the adaptive defense of the 
body’s cell-mediated immune response, the knee joint possesses inherent 
defense mechanisms against infection. The synovial fluid may contribute to 
a joint’s innate defense against certain microbial infections. However, the 
specific immunologic properties and protective mechanisms of synovial fluid 
against common gram-positive bacterial pathogens that are encountered 
clinically remain unknown (72).  
 
1.5 Animal Model for study of Periprosthetic Joint Infections 
 
 The increase in the number of periprosthetic infections in recent years 
and their consequent devastating results with an increase in morbidity and 
mortality, as well as high patient dissatisfaction and poor quality of life, has 
led to the development of animal models for the study of periprosthetic 
infections. Once established, such models are likely to transform our 
understanding of the pathogenesis of PJI and lead to novel treatments (73). 
 Carli et al. (74), in their recent study proposed four 4 standardized 
criteria that animal models should meet to be considered as clinically 
representative of PJI:  
1. Musculoskeletal and immunological properties comparable to those in 
humans. 
2. The implant utilized should be made of clinically relevant materials, bear 
load, and effectively reproduce the periprosthetic environment. 
3. The model should utilize clinically relatable bacteria and demonstrate 
biofilm formation on the implant surface. 
4. The model methodology should include quantitative measurements of 
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 The use of animals in research, teaching, and testing is acceptable only 
if it promises to contribute to understanding of fundamental biological 
principles, or to the development of knowledge that can reasonably be 
expected to benefit humans or animals. A continuing sharing of knowledge, 
review of the literature, and adherence to the Russell-Burch "3R" tenet of 
"Replacement, Reduction and Refinement" are also requisites. Those using 
animals should employ the most humane methods on the smallest number 
of appropriate animals required to obtain valid information (75). 
 
1.5.1 In vivo molecular imaging in animal models  
 
 In vivo molecular imaging in animals is an expanding discipline in 
biomedical research in the current post-genomic era. The advancement in 
molecular and cellular techniques, the increased numbers of animal models 
and the development of novel imaging systems have converted the non-
invasive in vivo imaging in an advantage tool over conventional 
cytology/histology microscopy techniques, which involve chemical fixation of 
removed tissues from which it can be difficult to generate quantitative data 
(76).  
 It is currently possible to develop non-invasive in vivo imaging of 
specific molecular and cellular mechanisms; to simultaneously monitor 
multiple molecular events; to track specific molecular targets; to optimise 
drug and gene therapy; to visualise drug effects at the molecular and cellular 
level; and to assess disease progression (77). 
 In addition, obtaining in vivo longitudinal imaging of the same animal 
model at multiple time points can achieve more valuable information than 
would be obtained from multiple individual models, avoiding the sacrifice of a 
large number of experimental animals. In these systems, the animal acts as 
its own control and the dynamic data show the progressive biological 
changes and the therapeutic response (78). 
 In recent years, there has been considerable progress in the 
development of non-invasive small animal in vivo imaging technology. The 
most popular techniques utilised by researchers are Magnetic Resonance 
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Tomography (PET) and optical imaging (bioluminescence and fluorescence) 
(78). 
  
1.5.1.1 Optical Imaging 
  
 This imaging modality produces excellent data from organs and 
structures close to the skin surface in small animals. This technique employs 
quantitative light emission i.e. photons to obtain measurements of relevant 
biological parameters, including proteins and nucleic acids within individual 
living cells. To detect low levels of light or photons, a very sensitive charge 
coupled device (CCD) detector is used. The CCD detector is capable of 
detecting light near-infrared range (NIR). There are two main forms of optical 
imaging, fluorescence imaging (FLI) and bioluminescence (BLI) (79). 
 In FLI, the visible light (395 to 600 nm) is used to excite fluorescence 
within the subject and a camera or fluorescent microscopy system detects 
the emitted light from the region of interest within the subject. The strategy is 
to fluorescently tag the cells, tissue or molecules under investigation with 
substances known to fluoresce. In the recent past, a popular choice has 
been the green fluorescent protein (GFP) which is derived from jellyfish 
Aequorea victoria. The wildtype GFP emits light at 509 nm, while its variant 
EGFP has a longer emitting wavelength and is 35-fold brighter.  Another 
popular fluorescent protein is the red fluorescence protein (RFP) DsRed, a 
faster maturing and more soluble variant of reef coral protein from the 
Discosoma species which allows more rapid appearance of red fluorescence 
and reduce the aggregation. Currently, new fluorescent probes were 
developed from a genetic modification of RFP such as mBanana, td-Tomato, 
mTangerine, mStrawberry and mCherry with longer emission wavelength 
and greater stability (78). 
 In BLI, light emission does not require excitation of the reporter. Light 
emission originates from an exergonic catalysis reaction of the substrate 
which releases photons of visible light. One common approach used in 
animal models is transfection of one of the luciferase family of photo-
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 The luciferase can be isolated either from the sea-pansy (Renilla 
reniformis) or from the North American firefly (Photimus pyralis). 
Furthermore, its expression can be controlled so that it is expressed only 
when required. Cells expressing luciferase can be easily identified through 
their emission of light in the range from 400 to 620 nm (79). 
 The main advantage of BLI over FLI is its capability to detect very low 
levels of light signal. In addition, in FLI, the external light source required for 
fluorochrome excitation could also generate background autofluorescence 
from animal tissues. However, an advantage over BLI is that FLI does not 
require administration of a substrate for visualisation. This overcomes the 
potential issues of difficult intravenous access in small animals (78).  
 
1.6 Project rationale 
 
 Periprosthetic infection is a leading cause of failure after total hip and 
knee arthroplasty. Infections remain a challenge for both patients and 
surgeons to treat and occur in approximately 1% of cases. It's still not clearly 
understood what the composition of the synovial fluid is of patients about to 
undergo these procedures. Owing to the increasing prevalence of resistant 
bacterial strains, and other factors, the likelihood of successful eradication of 
a chronic infection continues to decline, which is very challenging for the 
patient and surgeon and very expensive for a healthcare system with 
diminishing fiscal resources. 
 A better understanding of the environment in which the infection 
causing bacteria is growing could help lead to improved treatment strategies 
in the future.   
 This current study will serve as the foundation for a body of work, which 
is the result of a multidisciplinary collaboration with orthopaedics, 
microbiology and medical biophysics to work to solve the most challenging 
clinical problem facing arthroplasty patients and surgeons from the stand-
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1.7 Research objectives 
 
1.7.1 General objectives 
 
1. Study the behavior of S. aureus in the synovial fluid for a better 
understanding of these infections in the joints and leading to novel 
strategies in the treatment of periprosthetic joint infections.  
2. Develop a murine model of prosthetic joint infection that allows 
future studies for investigating the parameters involved in S. aureus 
infections after total joint replacements.  
 
1.7.2 Specific objectives 
 
1. Determine the effect of synovial fluid on S. aureus growth in-vitro. 
2. Determine which specific factors serve to affect bacterial growth in 
synovial fluid. 
3. Evaluate the behavior of three different strains of S. aureus into the 


























MATERIALS AND METHODS 
 
2.1 SYNOVIAL FLUID 
 
2.1.1 Ethics statements 
  
 Prior to patient enrollment for the synovial fluid collection, this research 
was approved Health Sciences Ethics Board of University Western Ontario 
and Lawson Research Institute. An informed consent was obtained from 
each patient prior to the surgery. 
  
2.1.2 Synovial fluid collection 
  
 The synovial fluids samples were obtained from ten patients undergoing 
elective primary total knee replacement for treatment of symptomatic end-
stage osteoarthritis. All samples were collected under sterile conditions by 
the same surgeon in the operating room at University Hospital. As per 
standard of care, to minimize the possibility of contamination with blood, a 
tourniquet was applied, and skin incision was carried out. Once the extensor 
mechanism and joint capsule were exposed, a sterile 18-gauge needle and 
20 cc syringe were used. The needle was introduced into the joint 
anteromedially and fluid was withdrawn from the knee. The samples were 
then analyzed in the Heinrichs Lab at Siebens Drake Research Institute of 
University Western Ontario.  
 Patients with severe medical comorbidities, a diagnosis of inflammatory 
arthropathy (i.e. rheumatoid arthritis, gout) or a diagnosis of fibromyalgia 
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 The samples of synovial fluid collected were labelled as sample 1, 2, 
etc. No identifiable data were retained with the samples. After analysis was 
complete, the samples were destroyed. 
 Patients were monitored at their standard follow-up appointments with 
the surgeon for adverse events and complications according to the standard 
of care at our institution. There was no follow-up monitoring for this study. 
 
2.1.3 Synovial fluid preparation 
  
 After sterile collection in the operating room at University Hospital, the 
synovial fluid samples were transported to Dr. Heinrichs Lab at the Siebens 
Drake Research Institute of University Western Ontario.  
 These were centrifuged at 5000 rpm for 10 minutes within 12 hours of 
collection to remove any possible blood cell contamination. The cell-free 
supernatant of synovial fluid was aspirated and transferred to cryovials using 
sterile technique. The samples then were transferred to a -80°C freezer for 
storage until final analysis. 
 The samples that did not centrifuge to a clear supernatant were 
discarded and excluded from analysis. 
 
2.1.4 Bacteria strain and culture conditions 
  
 S. aureus strains; UAMS-1 (osteomyelitis isolate) (80), USA300 
(plasmid cured) (81), USA300 graS (16), SH1000 (82), RN6390 (83), 
Newman (84), and Newman sfasbn (85) were used in this study (Table 
4). Bacteria were routinely cultured at 37°C in tryptic soy broth (TSB) (Difco) 
with shaking or on TSB agar (1.5% w/v). When necessary bacteria were 
cultured in the presence of 50 µg/mL kanamycin, 4 µg/mL tetracycline, or 
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Table 4: Bacteria strains used in Synovial fluid assays 
















UAMS-1; Osteomyelitis isolate 
 
USA300 LAC; MRSA cured of antibiotic 
resistance plasmids 
 
Derivative of S. aureus USA300 with graS 
created by pKOR mutagenesis 
 
WT S. aureus strain derived from 8325-4 
 
Prophage-cured wild-type strain 
 
Wild-type clinical osteomyelitis isolate 
 







Flannagan. 2018 (16) 
 
 
Horsburgh. 2002 (82) 
 








2.1.5 In-vitro synovial fluid analysis 
 
2.1.5.1 Synovial fluid growth assay 
  
 Synovial fluid samples from different donors were thawed and in-vitro 
growth analyses were performed using various S. aureus strains. Overnight 
cultures of each strain were grown in TSB and then diluted to and OD600 of 
1.0 in saline. Tubes containing a series of 2 fold dilutions of the synovial fluid 
in RPMI medium were inoculated with 10L of the OD=1 suspension for 
each strain to achieve a starting OD600 of 0.01 for each tube.  
 Two common restriction mechanisms employed by the host are the 
production of antibacterial proteins and limitation of bacterial access to 
nutrients such as iron. By inactivating antibacterial proteins such as the 
complement system or by adding exogenous iron sources we can 
investigate whether these specific immune mechanisms are active in 
synovial fluid. For these reason, in certain experiments exogenous iron was 
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synovial fluid was heated at 55° C for 1 hour to inactivate heat sensitive 
proteins prior to dilution in RPMI.  
 After 37° C incubation for 24 hrs, the bacteria were serially diluted and 
plated on tryptic soy agar (TSA) and incubated overnight at 37° C to 
determine the number of colony forming unit per ml (CFU/mL). 
 
2.1.5.2 Bacterial viability assay 
  
 Bacterial viability assay was performed in saline solution containing 
synovial fluid with and without additional iron to determine if the synovial 
fluid can kill various strains mutants of S. aureus rather than simply 
preventing growth. Synovial fluid samples from different donors were thawed 
and tubes containing either 20% or 50% of synovial fluid in saline solution 
were prepared. Tubes containing saline without synovial fluid were included 
as a negative control and when necessary 25mM FeCl3 was added to the 
synovial fluid samples. Overnight cultures of all of the strains tested were 
grown in TSB then diluted in saline and the samples were inoculated at an 
initial OD600 of 0.01. All of the samples were plated on TSA at time 0 to 
confirm all samples started with an equivalent number of CFU/mL. The 
samples were then incubated at 37°C for 24 hours after which they were 
again plated on TSA to determine the number of CFU/mL remaining. 
 
2.1.5.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) / Mass Spectrometry 
  
 Synovial fluid samples were thawed and diluted to an initial 
concentration of 20% in saline. Two-fold dilution series were then generated 
and mixed at a 1:1 ratio with Laemmli and the samples were boiled for 10 
minutes. After cooling, 7L of each dilution was loaded and ran on a 12% 
sodium dodecyl sulfate polyacrylamide gel in Tris-glycine buffer at 150V, 
and 500mA for 90 minutes. Upon completion the gel was removed from the 
dock and stained overnight with InstantBlue. After staining the gel was 
taken to the department of biochemistry where an automated spot picker 
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then sent for digestion and matrix associated laser desorption ionization-
mass spectrometry (MALDI-MS) by the Department of Biochemistry. 
 
2.1.5.4 Centricon filtered synovial fluid growth assay 
  
 Synovial fluid samples from different donors were thawed and diluted in 
RPMI containing either 20% or 5%. The synovial fluid samples were filtered 
using an Amicon ultra centrifugal filter units with a 30 kDa MW cut‐off for 20 
minutes. The filtrate containing proteins below 30 kDa and the concentrate 
containing proteins above 30 kDa were re-suspended in their initial culture 
volume. The filtered samples along with unfiltered control were used to 
make a series of dilutions (20, 10, 5, 2.5, 1.25, 0,612 and 0 %) of the 
synovial fluid. These tubes were inoculated at an initial OD600 equivalent 
0.01 and after 24 hours incubation at 37°C the samples were plated on TSA 
to determine the number of CFU/mL. 
 
2.1.5.5 Statistical Analysis 
  
 Data are presented as the mean ± SD. All statistical analyses and 
graph production were done through GraphPad Prism (GraphPad Software, 
La Jolla, CA). Data were analyzed using unpaired t-tests or a one-way 
analysis of variance with either Dunnett’s or Bonferroni’s multiple 
comparison test as indicated. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
 
2.2 ANIMAL MODEL OF S. AUREUS PERIPROSTHETIC JOINT 
INFECTION (pilot study) 
 
2.2.1 Ethics statements 
  
 The animal protocol was reviewed and approved by the University of 
Western Ontario Animal Use Subcommittee, according the guidelines set 
out by the Canadian Council on Animal Care. The study was conducted in 
strict accordance with the recommendations in the Guide by the Canadian 
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2.2.2 Mice 
  
 Three female C57BL/6 mice (Charles River Laboratories, Canada) (12 
weeks old) were used for periprosthetic joint infections animal models.  
 
2.2.3 Bacterial strains 
 
 Three different S. aureus subsp. aureus strain USA300 were used in 
animal models: USA300 wild-type, fhuCBG::ermC mutant strain (86) and 
purR::ΦNΣ mutant strain (87) (Table 5). 
 
Table 5: Bacteria strains used in animal models 










USA300 LAC; MRSA cured of antibiotic resistance 
plasmids 
 
Derivate of S. aureus Newman with fhuCBG operon 
deletion derivative of S. aureus  
 
Strain USA300 LAC containing a transposon insertion 













2.2.4 Mouse surgical procedures 
  
 Mice were anesthetized with isoflurane in a laminar flow hood. The mice 
were placed on their back and the operative leg was maximally flexed at the 
knee. Using a #15 scalpel blade, an anterior longitudinal midline incision 
was made centered over the knee. A subsequent incision was made just 
medial to the patella and extensor mechanism. The extensor mechanism 
was subluxated laterally and the distal end of the femur was identified. A 25-
gauge needle was used to open the femoral canal. A medical-grade 
stainless steel Kirschner wire (K-wire) (0.6 mm) was surgically placed into 
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mm protruding into the knee joint space. Surgeries were performed by 
myself under sterile conditions.  
 S. aureus (2x105 CFU in 2 μL saline) were inoculated into the joint 
space using a Hamilton syringe. The patella was relocated and the surgical 
incision was closed with Vicryl 5-0 sutures.  
 A high-resolution X-ray was taken immediately after the surgery to 
ensure proper placement of the implant. Buprenorphine (0.1 mg/kg) was 




Figure 4: (A) Mouse surgical procedure: The knee was maximally flexed and a 3-5 mm 
longitudinal incision was made centered over the knee. Medial parapatellar arthrotomy was 
performed and a 27-gauge needle was used to create an entry portal to distal femur. (B) and (C) 
Imaging: High-resolution X-ray was taken after the surgery to ensure proper placement of the 
k-wire implant. 
 
2.2.5 Quantification of in vivo S. aureus (In vivo bioluminescence 
imaging) 
  
 In vivo bioluminescence was performed with the IVIS imaging system at 
the Robarts Research Institute (London, ON, CA) at 7, 14, 21, 28, 35 and 42 
postoperative days.  
 Mice were anesthetized with isoflurane. Data are presented on color 
scale overlaid on a grayscale photograph of mice and quantified as total flux 
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2.2.6 In-vitro growth analysis 
  
 The mice were sacrificed at postoperative day 42. The implants were 
removed and the proximal aspect of the tibia, the distal aspect of the femur 
and implant were cut into small pieces and placed into sterile, 5-mL 
centrifuge tubes (Eppendorf) containing 2 mL of 4°C PBS + 0.1% Triton-
X100 solution. The contents were homogenized for 5 minutes (Bullet 
Blender; Next Advance) at setting 16, diluted in 4°C TSB, and then plated by 
duplicate on TSA to determine the number of CFU/mL in the periprosthetic 
tissues and implant. These samples also were plated on TSA with 
chloramphenicol, which allows us to determine the bacteria recovered still 


























3.1 S. AUREUS GROWTH IN SYNOVIAL FLUID 
 
3.1.1 S. aureus UAMS-1 grows poorer in synovial fluid than S. aureus 
USA300 
  
 To initially explore the effect of synovial fluid on the growth of S. aureus 
in-vitro growth assays were performed using two strains of S. aureus, 
USA300 and UAMS-1. The control specimen with no synovial fluid 
demonstrated exponential growth as expected. In contrast, bacterial counts 
in all of the synovial fluid specimens were decreased compared to controls. 
Although, USA300 strain demonstrated a significant decrease (**P<0.01, 
***P<0.001, ****P<0.0001) of CFU/ml in all concentrations of synovial fluid, 
no bacterial death was demonstrated (Figure 5A). In contrast, the UAMS-1 
strain demonstrated greater sensitivity to the synovial fluid. A synovial fluid 
concentration of 2.5% or higher was sufficient to significantly reduce growth 
compared to the control (**P<0.01). Moreover, concentrations of 5% or 
higher prevented visible growth and in some cases resulted in bacterial 
death (***P<0.001, ****P<0.0001) (Figure 5B). Taken together, these data 
indicate that synovial fluid has antimicrobial properties and S. aureus UAMS-
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A)       B) 
 
Figure 5 In-vitro growth analysis in synovial fluid. In (A), USA 300 strain was used to inoculate 
tubes containing different concentrations of synovial fluid in RPMI and the CFU/mL of bacteria at 24 
hours was determined N=3. In (B), similar in-vitro growth assays were performed using UAMS-1 strain 
N=6. Statistical significance was determined by Dunnett’s multiple comparison test where *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001. Dashed lines the initial CFU/mL inoculated into each tube.  
 
3.1.2 Iron limitation contributes to the ability of synovial fluid to restrict 
the growth of S. aureus 
  
 The next objective was to determine the mechanism of bacterial 
restriction in synovial fluid. To this end in-vitro growth curves were 
performed in RPMI with synovial fluid that had either been heat inactivated 
(H.I.) or with the addition of 25uM FeCl3 (the latter serves to saturate the iron 
sequestering capacity of lactoferrin/transferrin). After 24 hours incubation at 
37°C, we found the additional iron significantly increased bacterial growth in 
10% and 20% synovial fluid samples compared to the control specimen 
(**P<0.01). No significant differences were found in 5% synovial fluid 
concentration or lower. The heat inactivation did not demonstrate significant 
variations in bacterial growth compared with the control (Figure 6). This 
together shows that iron restriction is one of mechanisms used by the host 
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Figure 6: UAMS-1 growth in treated synovial fluid. As before growth assays were performed with 
synovial fluid diluted in RPMI. The synovial fluid was either Heat inactivated at 55°C for 1 hour or 
exogenous iron was added in the form of 25M FeCl3 prior to inoculation with S. aureus UAMS-1. 
Tubes were incubated at 37°C for 24 hours and the CFU/ml was determined. Statistical significance 
was determined by Bonferroni’s multiple comparison test where *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001 N=3. Dashed line indicates the CFU/mL inoculated into each tube. 
  
3.1.3 Iron restriction in synovial fluid increases killing of S. aureus 
UAMS-1 
 
 Given that S. aureus UAMS-1 growth decreased due to iron restriction, 
the next step sought to determine whether the iron restriction simply 
prevents bacterial growth or if it can also contribute to the killing of UAMS-1. 
Bacterial viability assays were performed in tubes containing saline with 
20% synovial fluid with and without the addition of exogenous iron. The 
synovial fluid resulted in an obvious killing of UAMS-1 compared to saline 
alone controls, but the addition of FeCl3 did improve bacterial viability 
(Figure 7A and B). However, the addition of FeCl3 to synovial fluid did not 
restore viability to the level of the saline alone controls. It is worth noting that 
when the samples were sorted by each individual donor the statistical 
analysis showed no significant differences in survival due to a low number of 
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demonstrated a statistically significant increase of bacterial survival in the 
samples with iron additional compared with the synovial fluid alone 
(****P<0.0001) (Figure 7B). This confirms that iron is restricted in synovial 
fluid and this restriction results in increased killing of S. aureus UAMS-1. 
 
A)       B) 
 
Figure 7: In-vitro UAMS-1 viability assay in synovial fluid. In (A) Bacterial viability assays were 
performed with UAMS-1 in saline solution containing 20% synovial fluid from different donors with and 
without the addition of 25M FeCl3. The CFU/mL of bacteria was determined at the time of inoculation 
and 24 hours later in order to determine the percent survival from the inoculum N=2. In (B) a 
combined analysis was performed with all synovial fluid donors included n=12. Statistical significance 
was determined by Dunnett’s multiple comparison test where *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. Dashed lines separate the results of each donor. 
 
3.1.4 Synovial fluid can effectively kill multiple strains of S. aureus 
 
 Because this work previously found that USA300 was much more 
resistant to synovial fluid than UAMS-1, the next goal was to determine 
whether the synovial fluid is able to kill other strains of S. aureus. To test this 
notion, bacterial viability assays were performed with the following S. aureus 
strains: SH1000, RN6390, Newman and Newman sfasbn. 
 The synovial fluid in SH1000 demonstrated a significant decrease in the 
CFU/ml compared to the control saline (***P<0.001). The addition of FeCl3 
did appear to improve bacterial viability in SH1000 strain, compared to the 
synovial fluid samples without iron, although the increase was not 
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synovial fluid, yet the addition of iron restored viability to the level of saline 
alone control (Figure 8B). Furthermore, both Newman WT and the Newman 
sfasbn mutant were killed in the synovial fluid and did not show improved 
viability with the addition of FeCl3. Interestingly the sfasbn mutant which is 
defective for iron acquisition had ~3 fold reduced viability compared to the 
WT strain (Figure 8C-D). Taken together these data indicate that the 
synovial fluid can kill multiple different S. aureus strains and the ability to 
gather iron appears important for survival. However, it should be noted that 
unlike before, the presence of iron did not significantly improve the bacterial 
viability, likely attributable to a low number of replicates as most of the 
strains are trending towards significance.  
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C)           D)  
Figure 8: Different strains viability assays in synovial fluid. Bacterial viability assays were 
performed in saline solution containing 20% synovial fluid with and without additional of 25M FeCl3 
iron. The initial CFU/mL of each samples was determined and the tubes were incubated for 24 hours 
after which the sample was again plated to determine CFU/mL. (A) S. aureus SH1000 WT-strain N=3. 
(B) S. aureus RN6390 WT-strain N=3. (C) S. aureus Newman WT-strain N=5. (D) S. aureus Newman 
sfasbn mutant N=3. Statistical significance was determined by Bonferroni’s multiple comparison 
test where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
 
3.1.5 Transferrin is responsible for sequestering iron in synovial fluid 
 
 The amount of iron available in the host environment is reduced by 
sequestering proteins such as transferrin and lactoferrin (6). To determine if 
one or both of these proteins is responsible for limiting access to iron in the 
synovial fluid, we attempted to identify the presence of these proteins in 
synovial fluid. A 12% sodium dodecyl sulfate polyacrylamide gel was 
prepared and varying dilutions of synovial fluid were subjected to 
electrophoresis. The gel showed a significant amount of protein around 75 
kDa, the approximate size of transferrin or lactoferrin, is present in synovial 
fluid (Figure 9). Either transferrin or lactoferrin could be responsible for 
competing with bacteria to access any available iron in synovial fluid. To 
determine the specific identity of the 75kDa protein samples were sent for 
digestion and matrix associated laser desorption ionization-mass 
spectrometry (MALDI-MS). This analysis confirmed that the 75kDa protein 
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supporting the previous observation that bacterial access to iron is restricted 















Figure 9: Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) Synovial fluid 
samples were diluted to a concentration range of 20%, 10%, 5% and 2.5% and 7L of each sample 
was loaded onto a 12% sodium dodecyl sulfate polyacrylamide gel. The gel was run for 90 minutes at 
150V and 500mA after which it was stained with InstantBlue to visualize the various proteins present 
in the synovial fluid Samples were sent for Mass spectrometry at the department of biochemistry at 
the University of Western Ontario. Boxed are the 75kDa marker (right) and the synovial fluid bands 
identified at transferrin. 
 
3.1.6 Synovial fluid containing high molecular weight proteins reduce 
the bacterial growth more than filtrate synovial fluid 
 
 The next objective was to confirm the role of transferrin in restricting 
bacterial growth in synovial fluid. In vitro growth experiments were performed 
using synovial fluid that had been separated into fractions containing proteins 
larger (with transferrin) and smaller (without transferrin) than 30kDa 
(concentrate and filtrate respectively). The growth of various strains of S. 
aureus was analyzed in the 2 fractions of filtered synovial fluid. It was found 
that the synovial fluid concentrate, which would contain transferrin, 
significantly reduced the growth of both UAMS-1 and RN6390 compared to the 
filtrate which lacks transferrin (Figure 10). Importantly the Newman WT and 
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filtrate and concentrate due to a low number of replicates, but the trend is clear 
and the data are trending to significance. All together this demonstrates a 
clear role for transferrin as a restrictive factor in synovial fluid that functions by 
iron starving the bacteria sensitizing them to killing by some other unknown 
factor.  
 
A)       B) 
 
C)       D) 
 
Figure 10: Centricon filtered synovial fluid growth assay. 30kDa molecular weight cut off filter to 
separate the fluid into fractions containing proteins above (concentrate) or below 30kDa (filtrate). 
Dilution series of the filtrate and concentrate were inoculated with the various strains and incubated for 
24 hours after which the samples were plated to determine the CFU/mL In (A) UAMS-1 and in (B), 
RN6390 showed decreased CFU/mL in the concentrate. In (C), Newman WT and in (D) Newman 
sfasbn there was no statically significant differences. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 
N=3. Dashed lines indicate the inoculum CFU/mL. 
 
3.1.7 The absence of GraS makes S. aureus more susceptible in 
synovial fluid. 
 
While the presence of transferrin in the synovial fluid explains the iron 
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work causing the bacterial killing. To begin to investigate other factors that may 
be responsible for bacterial killing we sought to determine the effect of synovial 
fluid on a graS mutant of USA300. The graS is part of a two-component 
regulatory system that is required by S. aureus for resistance against 
antimicrobial peptides, meaning a graS mutant is highly sensitive to killing by 
antimicrobial peptides. To this end bacterial viability assays were performed 
with USA300 WT and graS. The WT USA300 showed no significant decrease 
in CFU/mL over 24 hours in synovial fluid compared to the same strain in saline 
alone (Figure 11). In contrast to WT, the graS mutant was much more 
sensitive to killing by the synovial fluid and had a 2-log decrease compared to 
the same strain in saline alone (**P<0.01 Figure 11). This finding suggests that 
there are likely antimicrobial peptides present in the synovial fluid that result in 
bacterial killing. 
 
Figure 11: The absent of GraS render S. aureus more susceptible. Bacterial viability assays were 
performed for the graS mutant and strain USA300 WT in 50% synovial fluid compared with saline 
solution alone. The CFU/mL of bacteria was determined immediately after inoculating each strain and 
again after 24 hour incubation. Percent survival was determined by dividing the CFU/mL at 24 hours 
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3.2 ANIMAL MODEL OF S. AUREUS PERIPROSTHETIC JOINT 
INFECTION (pilot study) 
3.2.1 In vivo bioluminescence imaging is able to monitor an animal 
model of periprosthetic infection. 
 
 In vivo bioluminescence images were made at 7, 14, 21, 28, 35, 42 
postoperative days (Figure 12). The Relative Light Units (RLU) emitted by S. 
aureus from the mice knee joint were decreasing progressively over the 
days. Although the WT strain demonstrated better signal in the first three 
weeks, it decreased quickly after post-operative day 21. In contrast, the 
purR::ΦΝΣ and fhuCBG::ery strains kept relatively stable after post-
operative day 21 (Figure 13). 
 
A)      B) 
 
 







INVESTIGATING THE PATHOGENESIS OF S. AUREUS IN THE PERIPROSTHETIC JOINT INFECTIONS 
E)      F) 
 
Figure 12: In vivo bioluminescence imaging in animal model of PJI. (A) Postoperative day 7. (B) 
Postoperative day 14. (C) Postoperative day 21. (D) Postoperative day 28. (E) Postoperative day 35. (F) 














Figure 13: Relative light units emitted from mouse knee over the time. 
 
3.2.2 Bacterial burden was found in periprosthetic soft tissues and 
implants. 
 
 We next sought to determine the bacterial burden in periprosthetic soft 
tissues and implants recovered. For this, in vitro bacterial growth analyses 
were performed in TSB and TSB with chloramphenicol. The growth on 
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bioluminescence genes and the associated chloramphenicol resistance 
marker. After 24 hours incubation at 37°C, the number of CFU/mL were 
determined.  
 All bone tissue samples demonstrated the presence of bacterial burden. 
In contrast, the results obtained from the culture of the implants showed 
variability, with bacteria recovered in only two samples, and with no clear 
association with a particular bacterial strain. 
 Although these findings demonstrate the feasibility of the model, in both 
bioluminescent tracking and recovery of bacteria, the size of the pilot study 
does not allow for statistical differences to be calculated.  
 
 
Figure 14: In vitro bacterial growth analysis allowed to determine the presence of bacteria in 
bone tissues and implants recovered from the animals. 
 
3.2.3 Correlation of CFU/mL to RLU and construct stability 
 
 Our next goal was to determine whether there was a correlation 
between the RLU emitted from the mouse knee with the number of bacteria 
recovered from the bone tissues and implants. In WT strain and purR::ΦNΣ 
mutant strain there was a clear correlation, with the strength of the signal 
relating to the number of bacteria recovered. In contrast, fhuCBG::ermC 
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were not able to observe a correlation in this mutant even though there was 
bacterial growth in the recovered bone tissues samples.  
 Taken together, these findings demonstrate the successful 
establishment of an animal model of PJI, which allows the temporal 
observation of disease progression and gives the ability to track different 
bacterial mutants. This is a powerful tool that will allow us to further study 
the specific S. aureus factors involved in the establishment and development 
of PJI and inform the design of novel preventative techniques. Nevertheless, 
the findings demonstrated here were a pilot experiment, and further 
conclusions will require the use of a higher number of animals for the 
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CHAPTER 4 
DISCUSSION AND FUTURES DIRECTIONS 
 
 The number of arthroplasty procedures performed every year is 
increasing, as a result of this, there is an anticipated increase in revision 
arthroplasty (24). Periprosthetic joint infection (PJI) is the leading cause of 
revision surgery, and is the most challenging complication after total joint 
replacement (23). Infections remain a challenge for both patients and 
surgeons to treat and occur in approximately 1% of cases. 
 S. aureus is an opportunistic human bacterial pathogen responsible for 
nosocomial and community-associated infections (80). Its genetic plasticity 
has facilitated the evolution of many virulent and drug-resistant strains, 
presenting a major and constantly changing clinical challenge. Despite this, 
there has been relatively little research regarding the pathogenic 
mechanisms in synovial fluid. This study demonstrated that S. aureus has a 
high in vitro sensitivity in synovial fluid. Synovial fluid can not only reduce 
bacterial growth, it can also kill bacteria. 
 It's still not clearly understood what the composition of the synovial fluid 
is of patients about to undergo joint replacements (67). Recent studies 
suggest that the synovial fluid may contribute to a joint’s innate defense 
against certain microbial infections (68). Iron is an essential micronutrient 
used by bacteria for their growth. Supported by the observation that the 
additional iron significantly increased bacterial growth compared to the 
control specimen, we were able to confirm that iron restriction is one of the 
mechanisms used for the host to prevent bacterial growth in synovial fluid. In 
addition, in our in vitro assays, we could observe that limited access to iron 
not only prevented bacterial growth, it was even killing bacteria. These 




INVESTIGATING THE PATHOGENESIS OF S. AUREUS IN THE PERIPROSTHETIC JOINT INFECTIONS 
 As previously noted, iron is essential for basic bacterial physiologic 
processes such as electron transport or nucleotide synthesis (6). However, 
free iron is virtually unavailable in host environments. Human molecules, 
such as protoporphyrins (heme) or proteins (ferritin, transferrin, lactoferrin, 
hemoglobin, etc.) sequester most of the iron from the extracellular space, 
competing with the bacteria for it (88). These glycoproteins have a high 
affinity for free iron. S. aureus indirectly steals iron from lactoferrin or 
transferrin through the production of siderophores. Siderophores are 
secreted small molecules that have an extremely high affinity for iron and 
outcompete host iron-binding proteins. Siderophore-iron complexes are 
recognized by cognate receptors on the bacterial surface permitting the theft 
of iron from lactoferrin or transferrin (89). The synovial fluid composition is 
still not well known. Through our in-vitro experiments, we could confirm a 
significant amount of protein around 75 kDa, the approximate size of 
transferrin or lactoferrin, is present in synovial fluid. After matrix associated 
laser desorption ionization-mass spectrometry mass spectrometry (MALDI-
MS), we confirmed that the 75kDa protein identified in the synovial fluid is in 
fact transferrin, which could be responsible for competing with bacteria to 
access any available iron in synovial fluid. Furthermore, after different 
assays using synovial fluid that had been separated into fractions containing 
proteins larger (with transferrin) and smaller (without transferrin) than 30kDa 
(concentrate and filtrate respectively) we were able to demonstrate that the 
synovial fluid concentrate significantly reduced the growth of different strains 
of S. aureus. This finding speaks to clear role of transferrin as a restrictive 
factor in synovial fluid that functions by either competing the bacteria for 
iron, or sensitizing them and killing by some other unknown factor. 
 While the presence of transferrin in the synovial fluid explains the iron 
limitation, it does not directly kill bacteria, so there must be another factor(s) 
at work causing the bacterial killing. To begin to investigate other factors that 
may be responsible for bacterial killing, we were able to determine the effect 
of synovial fluid on a GraS mutant of USA300. The GraS contributes to S. 
aureus survival in vivo in the acute stages of systemic infection and is part of 
a two-component regulatory system that is required by S. aureus for 
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sensitive to killing by antimicrobial peptides (16). Consistent with our 
observations, there are likely antimicrobial peptides present in the synovial 
fluid that result in bacterial killing. However more work is needed as the 
specific peptide(s) in the synovial fluid have not been identified and there 
may still be other factors that contribute to the restriction and/or killing of S. 
aureus in synovial fluid. 
 In light of limited treatment successes, persistence of poor patient 
outcomes, and an increasing number of infections, we need to develop 
animal models to enhance our fundamental understanding and treatment of 
PJI. Once established, such models are likely to transform our 
understanding of the pathogenesis of PJI and lead to novel treatments (74). 
An important factor to consider when investigating mechanisms pertinent to 
human infection is whether animal models accurately reflect clinical features 
of human disease (90). Currently it is possible to develop non-invasive in 
vivo images of specific molecular and cellular mechanisms to optimize gene 
and drug therapy, visualize the effects of medications and assess the 
progression of the disease (76). Furthermore, obtaining in vivo longitudinal 
images of the same animal model at multiple time points would avoid the 
sacrifice of a large number of experimental animals; in these systems, the 
animal acts as its own control and the dynamic data show the progressive 
biological changes and the therapeutic response (78). Given the diversity of 
S. aureus strains and their propensity to cause community- or hospital-
acquired infections, we performed a preliminary animal model with three 
different S. aureus strains (USA300 wild-type, fhuCBG::ermC mutant strain, 
and purR::ΦNΣ mutant strain). Our findings allowed us to establish an 
animal model of PJI and observe the progression of the infection over the 
several weeks. Although this model represents only preliminary work, and a 
greater number of repetitions is needed to obtain statistically significant 
conclusions, we have managed to create a successful animal model of 
periprosthetic infection that allowed us to follow the infection in vivo and 
obtain a correlation between the number of recovered bacteria from the 
bone tissues and the relative light units emitted from the knee of the mouse. 
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 In summary, while the observations in this thesis are expected to 
generate significant interest, there is still a lot of work to be completed. It 
was demonstrated that the synovial fluid is able to prevent and even kill 
different S. aureus strains through the presence of transferrin which 
competes with the bacteria for the extracellular iron, but clearly more work is 
needed as there may still be other factors that contribute to the restriction 
and/or killing of S. aureus in synovial fluid. We found there are likely 
antimicrobial peptides present in the synovial fluid that result in bacterial 
killing, however, the specific peptide(s) in the synovial fluid have not been 
identified yet. Lastly, we created a successful animal model of periprosthetic 
joint that will serve as the basis of new models to solve the most challenging 
clinical problem facing arthroplasty patients and surgeons from the stand-
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